The role of amyloid PET in imaging neurodegenerative disorders: a review
M Chapleau, L Iaccarino… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …
decades and has been approved for clinical use by the US Food and Drug Administration …
Clinical amyloid imaging
A Mallik, A Drzezga, S Minoshima - Seminars in nuclear medicine, 2017 - Elsevier
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of
Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and …
Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and …
[HTML][HTML] Amyloid PET imaging: applications beyond Alzheimer's disease
AM Catafau, S Bullich - Clinical and translational imaging, 2015 - Springer
As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers
a unique opportunity to detect the presence of this protein in the human body during life …
a unique opportunity to detect the presence of this protein in the human body during life …
Should we disclose amyloid imaging results to cognitively normal individuals?
Demonstration of brain accumulation of fibrillar amyloid-β protein via PET with amyloid-
specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing …
specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing …
Amyloid PET imaging in clinical practice
MA Kolanko, Z Win, F Loreto, N Patel, C Carswell… - Practical …, 2020 - pn.bmj.com
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
[HTML][HTML] Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?
Although it afflicts an estimated 26.6 million people worldwide—a figure that is expected to
quadruple by 2050—Alzheimer's disease (AD) has yet to be fully understood etiologically …
quadruple by 2050—Alzheimer's disease (AD) has yet to be fully understood etiologically …
Cerebral amyloid PET imaging in Alzheimer's disease
CR Jack, JR Barrio, V Kepe - Acta neuropathologica, 2013 - Springer
The devastating effects of the still incurable Alzheimer's disease (AD) project an ever
increasing shadow of burden on the health care system and society in general. In this …
increasing shadow of burden on the health care system and society in general. In this …
Clinical use and utility of amyloid imaging
Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …
Brain amyloid imaging
CC Rowe, VL Villemagne - Journal of nuclear medicine …, 2013 - Soc Nuclear Med
Imaging of brain β-amyloid plaques with 18F-labeled tracers for PET will likely be available
in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly …
in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly …